Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date Issued: June 9, 2026
Reporting Period: Current event announcement for June 2026
GSK plc announced the entry into an agreement to acquire Nuvalent, Inc., a Boston-based clinical-stage biopharmaceutical company focused on targeted oncology therapies. The transaction aligns with GSK's strategy to acquire assets with validated targets that address efficacy and tolerability limitations in existing standard-of-care therapies.
Key Financial Metrics and Transaction Details
- Transaction Value: Aggregate equity value estimated at $10.6 billion (£8.0 billion).
- Purchase Price: $124 per share in cash for all outstanding Class A and Class B common stock.
- Net Investment: Estimated at $9.4 billion (£7.1 billion) net of cash acquired.
- Premium: Represents a 40% premium to the last closing price and a 26% premium to the 30-day VWAP.
- Funding: Primarily from new and existing debt facilities plus cash; no impact expected on GSK's credit rating.
- Dividend Policy: GSK remains committed to its 70p expected dividend for 2026.
Material Changes and Strategic Impact
The acquisition introduces three key assets in lung cancer:
- Zidesamtinib (NVL-520): Late-stage ROS1 inhibitor for non-small cell lung cancer (NSCLC); FDA decision expected September 18, 2026.
- Neladalkib (NVL-655): Late-stage ALK inhibitor for NSCLC; FDA decision expected November 27, 2026.
- NVL-330: HER2 inhibitor currently in Phase I trials for HER2-altered NSCLC.
The deal provides a platform for expansion with GSK's B7-H3 antibody-drug conjugate (Ris-Rez). The acquisition is expected to be accretive to sales and core operating profit in 2027 and core EPS in 2029, inclusive of synergies and reprioritization.
Guidance and Outlook
- 2026 Guidance: No change to the full-year guidance range of 7-9% core operating profit and core EPS growth.
- EPS Impact: Assuming a Q3 2026 closing, GSK expects low single-digit percentage dilution to core EPS for FY 2026, FY 2027, and FY 2028.
- Long-term Ambition: The acquisition is incremental to the Group's existing ambition for sales of >£40 billion by 2031.
- Profit Contribution: Expected to strengthen core operating profit during the dolutegravir loss of exclusivity period (2028-2030).
Risks and Contingencies
- Closing Conditions: Subject to customary conditions, including the tender of a majority of Nuvalent shares and the expiration of the Hart-Scott-Rodino Act waiting period.
- Regulatory Approval: Product launches depend on FDA approvals for zidesamtinib and neladalkib in 2026.
- Financial Obligations: GSK will assume Nuvalent's existing revenue-sharing arrangements involving low-single-digit royalties payable to Royalty Pharma and Deerfield.
- Forward-Looking Statements: Actual results may differ materially due to risks regarding the timing of the tender offer, regulatory approvals, and the ability to realize anticipated benefits.
Investor Verification Checklist
- Verify the final closing date of the transaction, currently expected in Q3 2026.
- Monitor FDA decision dates for zidesamtinib (Sept 18, 2026) and neladalkib (Nov 27, 2026).
- Review the upcoming Schedule TO Tender Offer Statement and Schedule 14D-9 for detailed terms.
- Assess the impact of the assumed royalty payments to Royalty Pharma and Deerfield on future margins.
- Confirm the specific debt facilities utilized to fund the $9.4 billion net investment.